These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22286886)

  • 21. Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece.
    Skoura L; Metallidis S; Buckton AJ; Mbisa JL; Pilalas D; Papadimitriou E; Papoutsi A; Haidich AB; Chrysanthidis T; Tsachouridou O; Antoniadou ZA; Kollaras P; Nikolaidis P; Malisiovas N
    J Antimicrob Chemother; 2011 Dec; 66(12):2831-7. PubMed ID: 21933785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
    Yerly S; von Wyl V; Ledergerber B; Böni J; Schüpbach J; Bürgisser P; Klimkait T; Rickenbach M; Kaiser L; Günthard HF; Perrin L;
    AIDS; 2007 Oct; 21(16):2223-9. PubMed ID: 18090050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008.
    Stańczak GP; Stańczak JJ; Marczyńska M; Firlag-Burkacka E; Wiercińska-Drapało A; Leszczyszyn-Pynka M; Jabłonowska E; Małolepsza E; Dyda T; Zabek P; Horban A
    J Med Virol; 2010 Jul; 82(7):1291-4. PubMed ID: 20513098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
    Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
    Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
    J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba.
    Kourí V; Alemán Y; Pérez L; Pérez J; Fonseca C; Correa C; Aragonés C; Campos J; Álvarez D; Schrooten Y; Dekeersmaeker N; Imbrechts S; Beheydt G; Vinken L; Pérez D; Álvarez A; Soto Y; Vandamme AM; Van Laethem K
    J Clin Virol; 2012 Dec; 55(4):348-55. PubMed ID: 22981617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.
    de Mendoza C; Rodriguez C; Corral A; del Romero J; Gallego O; Soriano V
    Clin Infect Dis; 2004 Oct; 39(8):1231-8. PubMed ID: 15486849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.
    von Wyl V; Yerly S; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Francioli P; Bonhoeffer S; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2009 Apr; 48(7):979-87. PubMed ID: 19228107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.
    Jakobsen MR; Tolstrup M; Søgaard OS; Jørgensen LB; Gorry PR; Laursen A; Ostergaard L
    Clin Infect Dis; 2010 Feb; 50(4):566-73. PubMed ID: 20085464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of drug-resistant HIV type 1 at the time of initiation of antiretroviral therapy in Portland, Oregon.
    MacVeigh MS; Kosmetatos MK; McDonald JE; Reeder JL; Parrish DA; Young TP
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):337-42. PubMed ID: 22697610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
    Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genotypic resistance mutations to antiretroviral drugs in newly confirmed human immunodeficiency virus infectors in Beijing].
    Ye JR; Guo L; Lu HY; Xin RL; Zeng Y
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(21):1453-6. PubMed ID: 21914279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
    Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
    AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.
    Weinstock HS; Zaidi I; Heneine W; Bennett D; Garcia-Lerma JG; Douglas JM; LaLota M; Dickinson G; Schwarcz S; Torian L; Wendell D; Paul S; Goza GA; Ruiz J; Boyett B; Kaplan JE
    J Infect Dis; 2004 Jun; 189(12):2174-80. PubMed ID: 15181563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 genetic diversity and drug resistance among treatment naïve patients from Southern Brazil: an association of HIV-1 subtypes with exposure categories.
    Gräf T; Passaes CP; Ferreira LG; Grisard EC; Morgado MG; Bello G; Pinto AR
    J Clin Virol; 2011 Jul; 51(3):186-91. PubMed ID: 21622023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.